Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein
Author Information
Author(s): Klepsch Freya, Chiba Peter, Ecker Gerhard F.
Primary Institution: University of Vienna
Hypothesis
What are the binding modes of propafenone-type P-glycoprotein inhibitors?
Conclusion
The study identifies specific binding sites for propafenone-type inhibitors on P-glycoprotein, which could help in overcoming multidrug resistance.
Supporting Evidence
- Overexpression of P-glycoprotein is linked to multidrug resistance in cancer therapies.
- Five propafenone derivatives were docked into homology models of P-glycoprotein.
- The identified binding site overlaps with known binding areas of other P-glycoprotein inhibitors.
Takeaway
This study looks at how certain drugs bind to a protein that can make cancer treatments less effective, helping scientists understand how to make better medicines.
Methodology
The study used homology modeling and docking of five propafenone derivatives into models of P-glycoprotein to identify binding sites.
Limitations
The study relies on homology models due to the lack of high-resolution structures of human P-glycoprotein, which may introduce uncertainty.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website